DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $481,049,029 | +80.0% | 1,938,932 | +74.1% | 0.24% | +83.3% |
| Q2 2023 | $267,273,600 | +111907.1% | 1,113,640 | +17.6% | 0.13% | -3.6% |
| Q1 2023 | $238,622 | -22.9% | 946,759 | -18.8% | 0.14% | -19.9% |
| Q4 2022 | $309,431 | -99.8% | 1,165,815 | +84.4% | 0.17% | +76.3% |
| Q3 2022 | $163,293,000 | +13.2% | 632,207 | +11.1% | 0.10% | +9.0% |
| Q2 2022 | $144,258,000 | -6.8% | 569,017 | +7.8% | 0.09% | +7.2% |
| Q1 2022 | $154,838,000 | -48.0% | 527,866 | -41.7% | 0.08% | -45.0% |
| Q4 2021 | $297,896,000 | +169.4% | 905,433 | +149.3% | 0.15% | +125.4% |
| Q3 2021 | $110,571,000 | -37.1% | 363,195 | -44.6% | 0.07% | -38.0% |
| Q2 2021 | $175,874,000 | +60.3% | 655,369 | +34.5% | 0.11% | +36.7% |
| Q1 2021 | $109,686,000 | -69.1% | 487,320 | -69.5% | 0.08% | -69.1% |
| Q4 2020 | $355,345,000 | +182.0% | 1,599,646 | +173.4% | 0.26% | +64.1% |
| Q3 2020 | $126,006,000 | -5.4% | 585,173 | -22.3% | 0.16% | -14.8% |
| Q2 2020 | $133,199,000 | -8.6% | 753,265 | -28.4% | 0.18% | -44.0% |
| Q1 2020 | $145,666,000 | +206.0% | 1,052,417 | +239.3% | 0.33% | +445.0% |
| Q4 2019 | $47,609,000 | -58.8% | 310,200 | -61.3% | 0.06% | -67.2% |
| Q3 2019 | $115,690,000 | +15.3% | 801,021 | +14.1% | 0.18% | +21.2% |
| Q2 2019 | $100,319,000 | +66.8% | 701,920 | +54.1% | 0.15% | +65.9% |
| Q1 2019 | $60,151,000 | +3788.2% | 455,620 | +2937.5% | 0.09% | +4450.0% |
| Q4 2018 | $1,547,000 | -98.8% | 15,000 | -98.8% | 0.00% | -98.8% |
| Q2 2018 | $126,558,000 | -34.7% | 1,282,505 | -35.2% | 0.16% | -36.3% |
| Q1 2018 | $193,850,000 | +133.9% | 1,979,882 | +121.8% | 0.26% | +125.2% |
| Q4 2017 | $82,869,000 | +754.7% | 892,794 | +689.8% | 0.12% | +666.7% |
| Q3 2017 | $9,696,000 | -48.9% | 113,037 | -49.8% | 0.02% | -55.9% |
| Q2 2017 | $18,992,000 | +2024.4% | 225,051 | +2052.6% | 0.03% | +1600.0% |
| Q1 2017 | $894,000 | -98.1% | 10,455 | -98.3% | 0.00% | -98.0% |
| Q4 2016 | $46,561,000 | +21.1% | 598,168 | +21.9% | 0.10% | +53.1% |
| Q3 2016 | $38,453,000 | +761.4% | 490,537 | +1009.9% | 0.06% | +540.0% |
| Q2 2016 | $4,464,000 | +4.7% | 44,198 | -3.7% | 0.01% | +11.1% |
| Q4 2015 | $4,264,000 | -99.0% | 45,911 | -99.0% | 0.01% | -98.8% |
| Q2 2015 | $411,799,000 | +92.6% | 4,811,294 | +91.1% | 0.78% | +95.7% |
| Q1 2015 | $213,807,000 | +283.7% | 2,518,334 | +287.4% | 0.40% | +237.3% |
| Q4 2014 | $55,716,000 | -21.8% | 650,056 | -30.7% | 0.12% | -34.8% |
| Q3 2014 | $71,273,000 | -30.3% | 938,051 | -27.7% | 0.18% | -36.0% |
| Q2 2014 | $102,184,000 | +19.5% | 1,297,903 | +13.8% | 0.28% | +14.1% |
| Q1 2014 | $85,544,000 | -9.1% | 1,140,578 | -6.4% | 0.25% | -16.5% |
| Q4 2013 | $94,097,000 | +152.6% | 1,218,878 | +126.9% | 0.30% | +147.5% |
| Q3 2013 | $37,245,000 | +80.9% | 537,293 | +65.2% | 0.12% | +90.5% |
| Q2 2013 | $20,591,000 | – | 325,290 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |